WO2018129888A1 - 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用 - Google Patents

与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用 Download PDF

Info

Publication number
WO2018129888A1
WO2018129888A1 PCT/CN2017/092505 CN2017092505W WO2018129888A1 WO 2018129888 A1 WO2018129888 A1 WO 2018129888A1 CN 2017092505 W CN2017092505 W CN 2017092505W WO 2018129888 A1 WO2018129888 A1 WO 2018129888A1
Authority
WO
WIPO (PCT)
Prior art keywords
pbc
il21r
primary biliary
biliary cholangitis
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/092505
Other languages
English (en)
French (fr)
Inventor
刘向东
马雄
陈卫昌
史兴娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southeast University
Original Assignee
Southeast University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southeast University filed Critical Southeast University
Publication of WO2018129888A1 publication Critical patent/WO2018129888A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention belongs to the field of immunology, and specifically relates to an interleukin 21 receptor (IL21R) associated with primary biliary cholangitis and its use.
  • IL21R interleukin 21 receptor
  • PBC Primary biliary cholangitis
  • AMA PBC-specific anti-mitochondrial antibodies
  • the positive rate of AMA was found to be higher than 0.16% in middle-aged women. Medium is above 0.3% [5].
  • a positive rate of AMA (PDC-E2) was found to be higher than 0.05% in 8126 adults (18-83 years old) in Guangdong, and higher than 0.15% in middle-aged women.
  • a recent AMA screening of 19,012 residents in Shanghai found that 0.40% of men and 0.94% of women were positive for AMA, and 25 of them (0.13%) had PBC. With the aging of China's population, PBC will rapidly develop into a more common disease in China. It may reach 200,000 to 300,000 patients in 2025 and 35 to 500,000 patients by 2050.
  • Ursodeoxycholic acid is the only drug that effectively controls early PBC patients (especially those with no jaundice), but there is no cure, and the only way to save patients with advanced PBC is Liver transplantation is performed. China is a country with high incidence of viral hepatitis.
  • the clinical symptoms of PBC are similar to viral hepatitis.
  • PBC patients are often misdiagnosed as viral hepatitis or drug-induced hepatitis in the early stage, which seriously affects the diagnosis and treatment of patients with PBC. Therefore, early diagnosis and treatment of PBC patients has important social significance.
  • PBC has a strong genetic susceptibility, and the first-generation relatives of patients have a 100-fold higher incidence of PBC than the general population. According to reports from North America, Europe and Japan, the family incidence of PBC is 3.8-9%. In 2005, a large-scale survey in North America showed that the relative odds ratio of immediate family members of PBC patients was as high as 10.7. Analysis of identical twins in patients with PBC found a common incidence of 63%. In the past four years, our team has found three pairs of identical twin PBC patients in the survey of domestic PBC patients. The sister symptoms and onset time of the three pairs of patients are very close. Combined with international data, the identical pairs of PBC patients The common incidence rate of children 72.7%.
  • GWAS genome-wide association analysis
  • the North American PBC Cooperative Group which is a core member of the applicant, used GWAS and specific site high-density gene polymorphism analysis to conduct a cohort analysis of PBC patients and control populations in North America, confirming the genetic susceptibility of PBC and HLA-II antigens.
  • IL12A, IL12RB2, STAT4, IRF5, ch17q12-21, MMEL1 and SPIB are closely related, and it is revealed that abnormalities in IL12R signaling pathway and Toll-like receptor (TLR)/TNF signaling pathway may lead to PBC .
  • TLR Toll-like receptor
  • the first technical problem to be solved by the present invention is to provide an application of IL21R in the preparation of a product for detecting or assisting detection, screening or predicting primary biliary cholangitis.
  • the second technical problem to be solved by the present invention is to provide a series of single nucleotide polymorphism sites (SNPs) which are significantly associated with primary biliary cholangitis, and to find out which is associated with primary biliary cholangitis. Susceptibility correlates with the most prominent representative sites, thereby providing the use of said single nucleotide polymorphic sites (SNPs) for assessing susceptibility to primary biliary cholangitis.
  • SNPs single nucleotide polymorphism sites
  • a third technical problem to be solved by the present invention is to provide an application of IL21R in the preparation of an animal model of PBC.
  • a fourth technical problem to be solved by the present invention is to provide an application of IL21R in the preparation of a therapeutic drug for PBC.
  • the technical solution adopted by the present invention is:
  • the application of IL21R in preparing a product for detecting or assisting detection, screening or predicting primary biliary cholangitis is provided.
  • the expression level of IL21R in the liver tissue of patients with PBC is directly proportional to the degree of liver fibrosis; specific gene polymorphism of IL21R and PBC were found by genome-wide association analysis. The disease is closely related.
  • the second aspect provides a series of single nucleotide polymorphisms of IL21R that are significantly associated with susceptibility to primary biliary cholangitis.
  • the study was performed on 1122 Chinese Han PBC patients and 4036 normal subjects.
  • the HumanOmniZhongHua-8 (v1.1) scan was used to analyze the genome-wide association data, and the gene polymorphism (SNP) was classified.
  • SNP gene polymorphism
  • PLINK software was used to compare all the polymorphic loci. The frequency of multiple SNPs of the IL21R gene was significantly different between PBC and normal population.
  • the single nucleotide polymorphism site with IL21R is: rs1859308, the allele is C/T; rs201883233, the allele is A/C; rs10852316, the allele is C/A; rs2189521, the allele is A. /G; rs58579343, the allele is A/G.
  • the present invention finds a linkage relationship between a plurality of SNPs and rs10852316 and rs2189521 by performing linkage disequilibrium analysis on SNPs at the IL21R site. Sequenom's iPlex method was used to verify the rs10852316 and rs2189521 polymorphism sites; and the Impute2 and PLINK software were used to perform the logistic regression principle. The sex was used as the covariate and analyzed by the additive effect model; similarly, significant differences were found. All of the SNPs in Table 1 are genetic polymorphic sites that are significantly different between PBC and control and can be used for risk prediction of PBC.
  • the present invention analyzes and evaluates the relationship between each SNP locus and primary biliary cholangitis by using PLINK software, logistic regression principle, and calculates the relative risk (ORd ratio, OR) of the dangerous allele and 95
  • the % confidence interval yields a dangerous allele for this series of SNP loci.
  • the risk alleles of the SNP locus of IL21R are: rs1859308 polymorphism site is C; rs201883233 polymorphism site is A; rs10852316 polymorphism site is C; rs2189521 polymorphism site is A; rs58579343
  • the polymorphic locus is A.
  • the present invention specifically analyzes 30 patients with PBC, 30 patients with autoimmune hepatitis (AIH), 25 patients with chronic hepatitis B (CHB), and 6 normal controls (HC) by histochemical analysis of IL21R.
  • AIH autoimmune hepatitis
  • CHB chronic hepatitis B
  • HC normal controls
  • an animal model established in the present invention introduces IL21R expression or activates a PBC animal model, and the model is used for screening of a PBC therapeutic drug.
  • the present invention has the following features and advantages:
  • the present invention found for the first time that multiple polymorphisms of IL21R are significantly associated with the occurrence of PBC, and can be used as one of the indicators for predicting the risk of PBC.
  • IL21R is significantly elevated in the liver tissue of PBC patients and is a target for PBC targeted therapy.
  • FIG. 1 is a correlation diagram of a single nucleotide polymorphism site of the IL21R gene region and PBC determined in Example 1.
  • the abscissa "Position on chr” is a position on a chromosome (unit: Mb);
  • the coordinates are the P value of the single nucleotide polymorphism site associated with PBC (-log10 (p-value)), the right Recombination rate is the recombination rate, the unit (CM/Mb); the representative locus rs2189521 to ⁇ Said.
  • Figure 2 is a histochemical analysis of IL21R in Example 3 in 30 patients with PBC, 30 patients with autoimmune hepatitis (AIH), 25 patients with chronic hepatitis B (CHB), and 6 normal controls (HC) in liver tissue sections.
  • expression. 2A is the expression of IL21R in a liver tissue section of a patient with PBC in Example 3.
  • 2B is the expression of IL21R in the liver tissue section of a patient with AIH in Example 3.
  • 2C is the expression of IL21R in the liver tissue section of a patient with CHB in Example 3.
  • 2D is the expression of IL21R in a liver tissue section of an HC tissue in Example 3.
  • 2E is a statistical analysis of the expression of IL21R in 30 patients with PBC, 30 patients with AIH, 25 patients with chronic hepatitis B (CHB), and 6 normal (HC) liver tissue sections in Example 3 (** * is P ⁇ 0.001, ** is P ⁇ 0.01).
  • Fig. 2F is a result of analysis of the correlation between the expression of IL21R in liver tissue sections of 30 patients with PBC and the degree of inflammation of liver tissue in PBC patients in Example 3.
  • 2G is a result of analysis of the correlation between the expression of IL21R in liver tissue sections of 30 PBC patients and the degree of liver tissue fibrosis in PBC patients in Example 3.
  • the HumanOmniZhongHua-8 (v1.1) analysis kit manufactured by Illumina Co., Ltd. includes a chip and a reagent.
  • Phosphate buffer 8 g NaCl, 0.2 g KCl, 0.24 g KH 2 PO 4 , 3.628 g Na 2 HPO 4 ⁇ 12H 2 O, double distilled water to 1 L;
  • Tris-HCl buffer pH 8.0: 30.3g Tris base dissolved in 200ml double distilled water, hydrochloric acid to adjust pH Value to 8.0, constant volume to 250ml;
  • nuclear lysis buffer (Nuclei Lysis Buffer, 500ml): 40ml 5M NaCl, 2ml 0.5M EDTA (pH 8.0), 5ml 1M Tris-HCl (pH 8.0), 453ml double distilled water;
  • Proteinase K buffer (Proteinase K buffer, 100ml): 50ml glycerol, 100ul 1M Tris-HCl (pH 7.5), 200 ⁇ l 1M CaCl 2 , 47ml double distilled water;
  • Proteinase K (Proteinase K Solution, 10mg / ml): 100mg proteinase K powder dissolved in 10ml proteinase K buffer;
  • TE buffer 1ml 1M Tris-HCl buffer (pH 8.0), 0.2ml 0.5M EDTA (pH 8.0), double distilled water to 100ml;
  • TAE buffer 242g Tris-base, 57.1ml glacial acetic acid, 200ml 0.5M EDTA (pH 8.0), double distilled water to 1L.
  • the present invention finds the association of the IL21R gene locus with primary biliary cholangitis by the following methods and procedures.
  • Non-anticoagulant therapy of patients and normal subjects was collected by non-anticoagulative collection tubes from various hospitals.
  • the collection tube was centrifuged to separate serum and blood clots.
  • the serum of the upper layer of the thawed blood sample was gently mixed with a pipette in a clean bench, and each was placed in four 1.5 ml screw cap storage tubes and stored at -80 °C.
  • the HumanOmniZhongHua-8 (v1.1) chip was purchased from ILLUMINA, and the classification was carried out in accordance with the requirements of the product method. The exact steps are based on the experimental steps of the Illumina HumanOmniZhongHua-8 (v1.1) chip. The relevant description can be found in the published literature [Adler, AJ, Wiley, GB, Gaffney, PM Infinium Assay for Large-scale SNP Genotyping Applications .J.Vis.Exp. (81), e50683, doi: 10.3791/50683 (2013).]. Each DNA sample was treated at 200 nanograms (ng) in strict accordance with the experimental procedure described in the Illumina HumanOmniZhongHua-8 (v1.1) chip.
  • the HumanOmniZhongHua-8 (v1.1) chip typing data was processed and output by the BeamadStudio software of ILLUMINA, and the associated data analysis was performed according to the published literature [Zuo, X. et al. Whole-exome SNP array identification 15new susceptibility loci for psoriasis .Nat Commun 6,6793,2015].
  • the classification data output by BeadStudio is analyzed by PLINK, and the duplicate and affinity samples are excluded according to the pairwise identity-by-state. Using smartpca software, the heterogeneous samples were excluded according to the principle component analysis. The results of 1,122 PBC patients and 4,036 normal controls were used for statistical analysis.
  • SNPs with a success rate of less than 98% exclude SNPs with a minimum allele frequency (MAF) of less than 0.01 in the analysis sample, and exclude Hardy–Weinberg equilibrium values of P ⁇ 1 ⁇ 10 -4 in normal control samples. SNP. After exclusion, a total of 776,516 autosomal SNPs were used for comparison.
  • PLINK software SNP correlation analysis uses the principle of linear regression, using gender as the covariate, using the additive allelic effect, assessing the significance of each SNP locus associated with PBC, and calculating the dangerous alleles.
  • the relative risk of the gene (Odds ratio, OR) and the 95% confidence interval, the OR value, confidence interval and P value were obtained directly in the analysis, thereby obtaining the dangerous allele of the site.
  • the significance level (P value) associated with each PBC in the SNP chip was calculated by genome-wide association (GWAS) analysis, and the chromosomal region with potential association with PBC was found according to the significance level (P value less than 0.0001). And obtain a single nucleotide polymorphism site and its allele that are significantly associated with PBC susceptibility.
  • the SNP calculation (Imputation) is based on the results of the Han people in the thousand human genome project (Reference), using IMPUTE2 software, combined with the results of 1,122PBC patients and 4,036 normal controls.
  • Linkage disequilibrium (LD) between single nucleotide polymorphisms in a chromosomal region refers to a non-random combination between different single nucleotide polymorphism sites, represented by r2 (0 -1).
  • the series of single nucleotide polymorphisms and their alleles are: rs6498017, allele is G/A; rs757374, allele is G/A; rs722516, allele is A/G; rs722517 The allele is C/T; rs1107788, the allele is T/C; rs11074854, the allele is C/G; rs1859309, the allele is T/C; rs1859308, the allele is C/T; rs1859307
  • the allele is A/G; rs201883233, the allele is A/C; rs1859306, the allele is G/A; rs11074855, the allele is T/C; rs10852316, the allele is G/T; rs7199163
  • the allele is G/T; rs982204, the allele is A/G; rs72535012, the all
  • the risk alleles were: rs6498017 polymorphism site G; rs757374 polymorphism site G; rs722516 polymorphism site A; rs722517 polymorphism site C; rs1107788 polymorphism site T; rs11074854 polymorphism site is C; rs1859309 polymorphism site is T; rs1859308 polymorphism site is C; rs1859307 polymorphism site is A; rs201883233 polymorphism site is A; rs1859306
  • the morphological locus is G; the rs11074855 polymorphism is T; the rs10852316 polymorphism is G; the rs7199163 polymorphism is G; the rs982204 polymorphism is A; the rs72535012 polymorphism is CTT; rs1116973 polymorphism site is T; rs238
  • IL21R gene region single nucleotide polymorphism site sequence
  • OR (95% CI) indicates the relative risk of developing PBC in individuals carrying disease-related haploids compared to individuals carrying normal haploids.
  • the chromosomal location is referred to Human Genome GRCh37/hg19.
  • PCR amplification primers and single base extension primers for the SNP site to be tested were designed using Sequenom Genothyping Tools and MassARRAY Assay Design software and synthesized by Integrated DNA Technologies.
  • Primer 1 sequence ACGTTGGATGGGTTATTTTTCCCAGATTCC;
  • Primer 2 sequence ACGTTGGATGCTGGGTGGTGGGAATTTTTA
  • Primer 1 sequence ACGTTGGATGTGTCAGCCACACTCAGGGA;
  • Primer 2 sequence ACGTTGGATGAGACCCACTGGCGTCTCTCT;
  • PCR amplification was performed using a multiplex PCR technique in a 384-well plate with a total volume of 5 ⁇ l per reaction system.
  • a PCR master mix solution was prepared in a new 1.5 ml EP tube.
  • the 384-well plate is a PCR reaction plate. Take out the prepared DNA sample 384-well plate, adjust the sample volume to 1 ⁇ L using a 24-channel sampler, and each template solution contains 20-50 ng of template DNA, Hotstar Taq 0.5U, 0.5 pmol of each amplification primer. , 0.1 ⁇ l of 25 mM dNTPs.
  • the PCR reaction conditions were set on a 384-well compatible PCR machine: 94 ° C for 4 minutes; 94 ° C for 20 seconds, 56 ° C for 30 seconds, 72 ° C for 1 minute, 45 cycles; 72 ° C for 3 minutes; 4 ° C retention.
  • a 384-well PCR reaction plate was placed on a PCR machine to initiate a PCR reaction.
  • the PCR product was treated with SAP (shrimp alkaline phosphatase) to remove free dNTPs from the system.
  • the single base extension reaction system contained 7 ⁇ l of the SAP-treated PCR product and 2 ⁇ l of the EXTEND Mix solution (wherein each of the extension reaction primer mixtures was 0.94 ⁇ l, the iPLEX enzyme was 0.041 ⁇ l, and the extension mixture was 0.2 ⁇ l).
  • the PCR machine was started to perform a single base extension reaction.
  • MassARRAY Nanodispenser RS1000 spotter was started and the resin extended extension was transferred to a 384 well SpectroCHIP chip.
  • the spotted SpectroCHIP chip was analyzed using MALDI-TOF (matrix-assisted laser desorption/ionization–time of fligh), and the results were classified using TYPER 4.0 software (sequenom) and the results were output. . A total of 907 PBC samples and 2127 control samples gave valid results.
  • the results of 907 PBC samples and 2127 control samples were statistically analyzed by gender as the common variable.
  • the disease-related haploid (G) frequency of rs10852316 was significantly higher in the PBC (0.626) than in the control population (0.556), with a p-value of 5.59 ⁇ 10 -7 .
  • the disease-related haploid (A) frequency of rs2189521 was significantly higher in the PBC (0.754) than in the control population (0.680), and the p value was 9.87 ⁇ 10 -9 .
  • the GWAS results of 1,122 PBC patients and 4,036 normal controls were superimposed with the results of 907 PBC samples and 2127 control samples.
  • the principle of fixed-effect model (I2 ⁇ 25%) was used.
  • the statistical analysis included 2029 PBCs. Sample and 6163 control samples.
  • the results showed that the disease-related haploid (G) frequency of rs10852316 was significantly higher in PBC than in the control group, with a p-value of 2.76 ⁇ 10 -13 and a relative risk value (96% CI) of 1.32 (1.22-1.41); rs2189521
  • the disease-related haploid (A) frequency was significantly higher in the PBC than in the control population, with a p-value of 4.00 ⁇ 10 -16 and a relative risk value (96% CI) of 1.41 (1.28-1.52) (see Table 3).
  • Table 3 Results of IL21R polymorphism locus rs10852316, rs2189521 in genome-wide association analysis and validation findings
  • liver tissues including 30 patients with PBC, 30 patients with autoimmune hepatitis (AIH), and 25 patients with chronic hepatitis B (CHB) were ultrasound-guided liver biopsy at Shanghai Renji Hospital.
  • the liver tissue of 6 healthy controls (HC) was from a liver transplant donor. Liver tissues were preserved in formalin and embedded in paraffin. The degree of inflammation and fibrosis of liver tissue was assessed according to the "Scheuer" scoring system.
  • Liver tissue sections were soaked in sodium citrate buffer for 20 minutes;
  • IL21R was significantly increased in liver tissue of patients with PBC compared with hepatitis B, autoimmune hepatitis and normal liver tissue.
  • cells expressed by IL21R are usually clustered in the inflammatory portal area of the liver, especially around the lobular bile duct.
  • the experimental results show that the number of IL21R positive cells is proportional to the degree of inflammation in the liver and the degree of fibrosis in the liver.
  • Fig. 2 The relevant results are shown in Fig. 2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

提供了白细胞介素21受体(IL21R)在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎(Primary Biliary Cholangitis，PBC)的产品中的应用。与原发性胆汁性胆管炎易感性显著相关的白细胞介素21受体的单核苷酸多态位点为：rs1859308、rs201883233、rs10852316、rs2189521、rs58579343。IL21R的所述基因多态性位点与PBC的发生显著相关，可用于PBC发病风险预测的指标之一。

Description

与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用 技术领域
本发明属于免疫学领域，具体涉及与原发性胆汁性胆管炎关联的白细胞介素21受体(IL21R)及其应用。
背景技术
原发性胆汁性胆管炎(primary biliary cholangitis,PBC)，旧称原发性胆汁性肝硬化(primary biliary cirrhosis)，是一种累及肝内胆管系统的慢性进展性自身免疫性疾病，主要表现为肝内小胆管进行性破坏伴门脉炎症性改变，最终导致纤维化及肝硬化。本病主要发生于中年以上女性，男性病例仅占10％。随着对PBC疾病认识的不断提高和诊断方法的建立，PBC的发病率和患病率在全球呈上升趋势。2003年，在上海地区对5011个健康体检者的(26-85岁)PBC特异性抗线粒体抗体(AMA)(PDC-E2)进行筛查，发现AMA阳性率高于0.16％，在中年女性中高于0.3％[5]。2006年，在广东地区对8126个成年人(18-83岁)的普查中发现AMA(PDC-E2)的阳性率高于0.05％，在中年女性中高于0.15％。最近在上海地区对19012个居民的AMA筛查结果发现0.40％的男性和0.94％的女性AMA阳性，其中25人(0.13％)患有PBC。随着我国人口老龄化的加剧，PBC在我国将迅速发展成一种较常见的疾病，在2025年可能达到20-30万患者，到2050年可能高达35-50万患者。
早期诊断和治疗是控制PBC疾病发展的最有效手段。目前对PBC的治疗缺少有效的办法，熊去氧胆酸是唯一对早期PBC患者(尤其是黄疸没有出现的患者)进行有效控制的药物，但无治愈作用，而挽救晚期PBC患者的唯一手段是实施肝脏移植。我国是病毒性肝炎高发的国家，PBC的临床症状与病毒性肝炎相似，PBC患者早期常被误诊为病毒性肝炎或药物性肝炎，严重影响了PBC患者的诊疗。因此，对PBC患者进行早期诊断和治疗，具有重要的社会意义。
PBC具有很强的遗传易感性，患者的第一代亲属的PBC发病率比一般人群高100倍。综合北美、欧洲和日本的报道，PBC的家族发病率为3.8-9％。2005年，一项在北美的大规模调查结果显示，PBC病人直系亲属发病的相对危险度(odds ratio)高达10.7。通过PBC患者的同卵双生子进行分析，发现其共同发病率达63％。我们团队在过去四年对国内PBC患者的调查中发现了3对同卵双生的PBC患者，三对患者的姐妹发病症状和发病时间都非常接近，结合国际已有数据，PBC患者的同卵双生子共同发病率高达 72.7％。
自2009年以来，对白人PBC患者全基因组关联分析(GWAS)的一系列结果显示PBC具有很强的遗传易感性。以申请人为核心成员的北美PBC合作组采用GWAS和特定位点高密度基因多态性分析的方法，对北美PBC患者和对照人群进行队列分析，证实了PBC的遗传易感性与HLA-II类抗原、IL12A、IL12RB2、STAT4、IRF5、ch17q12-21、MMEL1和SPIB等位点密切相关，而且揭示了IL12R信号传导通路和Toll-like受体(TLR)/TNF信号传导通路的异常可能导致PBC的发生。日本学者的小规模的GWAS研究也发现了TNFSF15位点与PBC密切相关。我国对PBC的遗传学研究已有一定的基础，国内的学者分别就HLA和CTLA4等基因位点与汉族PBC遗传易感性进行了初步研究。
我们启动并完成了对1122例汉族PBC样品的Illumina中华芯片扫描工作，结合4046例对照数据，进行了大规模的队列分析，在国际上首次发现并证实了IL21R的基因位点达到了GWAS显著性，并首次发现IL21R在PBC患者血液中异常高表达，其表达程度与肝脏组织纤维化程度呈正比。
目前国际上尚无专利文献提及IL21R基因位点以及IL21R与PBC的关系。
发明内容
发明目的：本发明所要解决的第一个技术问题是提供了IL21R在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用。
本发明所要解决的第二个技术问题是提供了一系列与原发性胆汁性胆管炎显著相关的单核苷酸多态位点(SNP)，并找出其中与原发性胆汁性胆管炎易感性关联最显著的代表性位点，从而提供将所述的单核苷酸多态位点(SNP)用于评估原发性胆汁性胆管炎易感性的用途。
本发明所要解决的第三个技术问题是提供了IL21R在制备PBC动物模型中的应用。
本发明所要解决的第四个技术问题是提供了IL21R在制备PBC治疗药物方面的应用。
技术方案：为了解决上述技术问题，本发明所采用的技术方案为：第一方面，提供了IL21R在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用。我们启动并完成了对1122例汉族PBC样品的Illumina中华芯片扫描工作，结合4036例对照数据，进行了大规模的队列分析，在国际上首次发现并证实了IL21R的基因位点达到了GWAS显著性，并首次发现IL21R在PBC患者肝脏组织中表达程度与肝脏组织纤维化程度呈正比；具体通过全基因组关联分析，发现IL21R的基因多态性与PBC发 病有密切关系。
第二方面提供了一系列与原发性胆汁性胆管炎易感性显著相关的IL21R的单核苷酸多态位点，通过对1122例中国汉族PBC患者样品和4036例正常人样品为研究对象，使用了HumanOmniZhongHua-8(v1.1)扫描进行全基因组关联数据分析，进行基因多态性(SNP)的分型，利用芯片得到的数据，采用PLINK软件对所有多态位点的对比分析，发现IL21R基因的多个SNP的频数在PBC和正常人群中有显著差异。与IL21R的单核苷酸多态位点为：rs1859308，等位基因为C/T；rs201883233，等位基因为A/C；rs10852316，等位基因为C/A；rs2189521，等位基因为A/G；rs58579343，等位基因为A/G。
第三方面，本发明通过对IL21R位点的SNP进行连锁不平衡分析，发现多个SNP与rs10852316，rs2189521的连锁关系。采用Sequenom的iPlex方法，针对其中rs10852316，rs2189521多态性位点进行验证试验；并使用Impute2和PLINK软件，逻辑回归原理进行，以性别为共变量，按叠加效应模型分析；同样发现有显著差异；表1中的所有SNP均为在PBC和对照间有显著差别的基因多态位点，可用于对PBC的风险预测。
第四方面，本发明通过使用PLINK软件，逻辑回归原理进行分析评估每个SNP位点与原发性胆汁性胆管炎的关系，计算危险等位基因的相对危险度(Odd ratio，OR)和95％的可信区间，得到这一系列SNP位点的危险等位基因。IL21R的SNP位点的危险等位基因分别是：rs1859308多态性位点为C；rs201883233多态性位点为A；rs10852316多态性位点为C；rs2189521多态性位点为A；rs58579343多态性位点为A。
第五方面，本发明通过对IL21R特异的组织化学分析对30例PBC患者，30例自身免疫肝炎患者(AIH)，25例慢性乙型肝炎患者(CHB)，和6例正常对照(HC)的肝脏组织切片进行IL21R蛋白的表达进行测定，发现IL21R在PBC患者肝脏组织中显著升高(P<0.01)，IL21R的表达水平与PBC患者肝脏组织的炎症程度和纤维化程度呈正相关。
第六方面，本发明建立的动物模型中引入IL21R表达或激活制备PBC动物模型，并将此模型用于PBC治疗药物的筛选。
有益效果：本发明具有如下的特色和优点：
1)本发明首次发现IL21R的多个基因多态性位点与PBC的发生显著相关，可用于PBC发病风险预测的指标之一。
2)本发明发现IL21R在PBC患者肝脏组织中显著升高，是可用于PBC靶向治疗的靶点。
3)发明的发现有可能通过在动物模型中引入IL21R表达或激活制备PBC动物模型，并将此模型用于PBC治疗药物的筛选。
附图说明
图1为实施例1中所确定的IL21R基因区域单核苷酸多态性位点与PBC的关联图；图1中：横坐标“Position on chr”为染色体上的位置(单位Mb)；纵坐标为单核苷酸多态性位点与PBC的关联显著性P值(-log10(p-value))，右侧Recombination rate为重组率，单位(CM/Mb)；代表位点rs2189521以◆表示。
图2为实施例3中组织化学分析IL21R在30例PBC患者，30例自身免疫肝炎(AIH)患者，25例慢性乙型肝炎(CHB)患者，和6例正常对照(HC)肝脏组织切片中的表达。图2A为实施例3中在1例PBC患者组织肝脏组织切片的IL21R的表达。图2B为实施例3中在1例AIH患者组织肝脏组织切片的IL21R的表达。图2C为实施例3中在1例CHB患者组织肝脏组织切片的IL21R的表达。图2D为实施例3中在1例HC组织肝脏组织切片的IL21R的表达。图2E为实施例3中IL21R在30例PBC患者，30例AIH患者，25例慢性乙型肝炎(CHB)患者，和6例正常(HC)肝脏组织切片中的表达的统计分析结果(***为P<0.001，**为P<0.01)。图2F为实施例3中IL21R在30例PBC患者的肝脏组织切片中的表达与PBC患者的肝脏组织炎症程度相关性的分析结果。图2G为实施例3中IL21R在30例PBC患者的肝脏组织切片中的表达与PBC患者的肝脏组织纤维化程度相关性的分析结果。
具体实施方式
下面通过具体的实施例和附图对本发明进一步说明。
本发明实施例中所用实验材料、主要试剂及配方如下：
主要实验材料和主要试剂：
1、原发性胆汁性胆管炎患者和正常对照人群的DNA样品和血清；
2、全基因组关联分析芯片分析试剂盒：由Illumina公司生产的HumanOmniZhongHua-8(v1.1)分析试剂盒包括芯片和试剂。
主要溶液配制：
1、磷酸缓冲液(PBS，1L)：8g NaCl，0.2g KCl，0.24g KH2PO4，3.628g Na2HPO4·12H2O，双蒸水定容至1L；
2、饱和氯化钠溶液(5M NaCl，1L)：292.5g NaCl，双蒸水溶解定容至1L；
3、1M Tris-HCl缓冲液(pH 8.0)：30.3g Tris base溶于200ml双蒸水中，盐酸调节pH 值至8.0，定容至250ml；
4、0.5M EDTA(PH 8.0)：36.5g EDTA溶于NaOH溶液中，调节pH至8.0，定容至250ml；
5、核裂解缓冲液(Nuclei Lysis Buffer，500ml)：40ml 5M NaCl，2ml 0.5M EDTA(PH8.0)，5ml 1M Tris-HCl(pH 8.0)，453ml双蒸水；
6、蛋白酶K缓冲液(Proteinase K buffer，100ml)：50ml glycerol，100ul 1M Tris-HCl(pH7.5)，200μl 1M CaCl2，47ml双蒸水；
7、蛋白酶K(Proteinase K Solution，10mg/ml)：100mg蛋白酶K粉末溶于10ml蛋白酶K缓冲液中；
8、消化液(Nuclei-SDS-Proteinase K-Master Mix Lysis buffer，504ml)：420ml Nuclei Lysis Buffer，3.5ml Proteinase K(10mg/ml)，17.5ml 10％SDS，0.35ml 0.5M EDTA(PH 8.0)，62.65ml双蒸水；
9、TE缓冲液(PH 8.0)：1ml 1M Tris-HCl缓冲液(pH 8.0)，0.2ml 0.5M EDTA(PH 8.0)，双蒸水定容至100ml；
10、6×DNA点样缓冲液(10ml):88mg EDTA，5mg溴酚蓝，5mg二甲苯青，溶于4ml双蒸水中，再加入3.6ml甘油后使用NaOH调节至PH7.0，定容至10ml；
11、50×TAE缓冲液：242g Tris-base，57.1ml冰乙酸，200ml 0.5M EDTA(PH 8.0)，双蒸水定容至1L。
实施例1全基因组关联分析
本发明通过下述方法和步骤发现IL21R基因位点与原发性胆汁性胆管炎的关联。
一、方法
首先在中国汉族人群中选取了1122例中国汉族PBC患者样品和4036例正常人样品为研究对象，进行HumanOmniZhongHua-8(v1.1)扫描，进行基因多态性(SNP)的分型，采用PLINK软件对所有多态位点的对比分析，发现IL21R基因的多个SNP的频数在PBC和正常人群中有显著差异。
二、病例和对照样本入选标准
所有纳入研究的PBC患者均符合以下标准：1)、所有患者均为汉族；2)、AMA-M2血清学检测呈阳性；3)、生化指标显示胆汁淤积证据，主要表现为ALP，GGT升高；5)、各类肝炎病毒感染以及人类免疫缺陷病毒感染指标阴性(乙肝病毒表面抗原阴性、血清 中乙肝病毒DNA小于200拷贝数/毫升、血清中丙肝病毒RNA小于500拷贝数/毫升、戊肝抗原阴性、人类免疫缺陷病毒抗体阴性)；6)、无血吸虫感染史；7)病人主诉饮酒量小于100ml/日。
全基因组扫描对照人群样品来自安徽，江苏，山东的正常体检人群，生化指标正常，无临床疾病表征，自述体健。病例是22～85岁之间筛选，平均年龄为54.7岁；对照为15岁到96岁之间筛选，平均年龄为34.8岁。
三、测试人群的基本特征
测试人群为芯片检测样本其基本特征如下：
表1
Figure PCTCN2017092505-appb-000001
四、原发性胆汁性胆管炎(PBC)患者和正常对照人群的基因组DNA样品的制备
1、病人和正常人的非抗凝血由各医院采集在非抗凝血收集管中。将收集管离心，分离血清和血凝块。在超净工作台内将解冻的血样上层的血清用移液器轻轻混匀，均分装入4个1.5ml螺盖保存管，保存于-80℃。
2、用长柄勺取出分离胶，将血块倒入称量舟，用剪刀将血块充分剪碎，再用塑料吸管将碎血块转移至50ml离心管中。
3、用PBS缓冲液冲洗称量舟及采血管，回收清洗液至50ml离心管，用塑料吸管混匀液体，离心，2500rpm，15min，4℃，弃上清。
4、加5ml消化液，混匀，放入水浴恒温振荡器，50℃，200rpm，过夜消化。
5、消化完全后加1.5ml 5M NaCl，混匀；室温静置10min,期间颠倒混匀多次，离心，3800rpm，30min，室温。
6、转移上清于50ml离心管，加2倍体积无水乙醇，充分混匀。
7、用移液器将可见的絮状DNA沉淀转移至含有500μl 70％乙醇的2ml EP管进行清洗。
8、离心，13000rpm，5min，室温，弃上清；再离心，13000rpm，1min，室温，用移液器弃尽残液，晾干，用双蒸水溶解。
五、HumanOmniZhongHua-8(v1.1)芯片扫描分型和全基因组关联数据分析
HumanOmniZhongHua-8(v1.1)芯片购自ILLUMINA公司，分型按照产品方法要求进行。具体操作严格步骤按Illumina公司HumanOmniZhongHua-8(v1.1)芯片的实验步骤进行，相关描述可同样见发表的文献[Adler,A.J.,Wiley,G.B.,Gaffney,P.M.Infinium Assay for Large-scale SNP Genotyping Applications.J.Vis.Exp.(81),e50683,doi:10.3791/50683(2013).]。每个DNA样品采用200纳克(ng)，严格按照Illumina公司HumanOmniZhongHua-8(v1.1)芯片的说明实验步骤进行处理。
HumanOmniZhongHua-8(v1.1)芯片分型数据由ILLUMINA公司的BeadStudio软件处理并输出，关联数据分析按发表的文献同样进行[Zuo,X.et al.Whole-exome SNP array identifies 15new susceptibility loci for psoriasis.Nat Commun 6,6793，2015]。BeadStudio输出的分型数据采用PLINK分析，根据状态同一配对原理(pairwise identity-by-state)，排除重复样品和亲缘样品。采用smartpca软件，根据主成分分析原理(principal component analysis)，排除群体异质样品，共有1,122PBC病人和4,036正常对照的结果，用于统计分析。排除分型成功率低于98％的SNP，排除在分析样品中频率(minor allele frequency，MAF)低于0.01的SNP，排除在正常对照样品中Hardy–Weinberg equilibrium值P<1×10-4的SNP。经过排除，共有776,516个常染色体的SNP用于比较。采用PLINK软件，SNP相关分析采用线性回归的原理，以性别为共变量(covariate)，采用加性效应原理(additive allelic effect)，评估每个SNP位点与PBC关联的显著性，计算危险等位基因的相对危险度(Odds ratio,OR)和95％的可信区间，分析中直接获得OR值、可信区间和P值，从而得到所述位点的危险等位基因。通过全基因组关联(GWAS)分析计算获得SNP芯片中每个位点与PBC关联显著性水平(P值)，按照显著性水平(P值小于0.0001)找出与PBC之间存在潜在关联的染色体区域，并得到PBC易感性显著关联的单核苷酸多态性位点及其等位基因。SNP的推算(Imputation)是以千人基因组项目中汉族人结果为参考值(Reference)，采用IMPUTE2软件，结合1,122PBC病人和4,036正常对照的结果进行推算。
分析结果参见表2和图1，结果显示在IL21R基因区，有5个单核苷酸多态性位点 (rs1859308，rs201883233，rs10852316，rs2189521，rs58579343)的疾病相关单倍体频率在PBC中显著高于对照人群，p值为9.88×10-7-5.40×10-9。有15个SNP与rs1859308，rs201883233，rs10852316，rs2189521，rs58579343连锁不平衡(r2＝0.9-1)推算出对应的p值，均在PBC中显著高于对照人群(p＝9.63×10-7-6.41×10-8)。染色体区域单核苷酸多态性位点间的连锁不平衡(Linkage disequilibrium,LD)情况，指的是不同单核苷酸多态性位点间存在着的非随机组合，用r2表示(0-1)。这一系列单核苷酸多态性位点及其等位基因是：rs6498017，等位基因为G/A；rs757374，等位基因为G/A；rs722516，等位基因为A/G；rs722517，等位基因为C/T；rs1107788，等位基因为T/C；rs11074854，等位基因为C/G；rs1859309，等位基因为T/C；rs1859308，等位基因为C/T；rs1859307，等位基因为A/G；rs201883233，等位基因为A/C；rs1859306，等位基因为G/A；rs11074855，等位基因为T/C；rs10852316，等位基因为G/T；rs7199163，等位基因为G/T；rs982204，等位基因为A/G；rs72535012，等位基因为CTT/C；rs1116973，等位基因为T/A；rs2382582，等位基因为A/C；rs2189521，等位基因为A/G；rs58579343，等位基因为T/C。其中危险等位基因分别是：rs6498017多态性位点为G；rs757374多态性位点为G；rs722516多态性位点为A；rs722517多态性位点为C；rs1107788多态性位点为T；rs11074854多态性位点为C；rs1859309多态性位点为T；rs1859308多态性位点为C；rs1859307多态性位点为A；rs201883233多态性位点为A；rs1859306多态性位点为G；rs11074855多态性位点为T；rs10852316多态性位点为G；rs7199163多态性位点为G；rs982204多态性位点为A；rs72535012多态性位点为CTT；rs1116973多态性位点为T；rs2382582多态性位点为A；rs2189521多态性位点为A；rs58579343多态性位点为T。(见表2)。携带这些危险等位基因的个体发生PBC的相对风险是没有携带者的1.32-1.41倍。
IL21R基因区域单核苷酸多态性位点序列：
如序列表中的SEQ ID NO.1所示：
rs6498017
Figure PCTCN2017092505-appb-000002
如序列表中的SEQ ID NO.2所示
rs757374
Figure PCTCN2017092505-appb-000003
如序列表中的SEQ ID NO.3所示
rs722516
Figure PCTCN2017092505-appb-000004
如序列表中的SEQ ID NO.4所示
rs722517
Figure PCTCN2017092505-appb-000005
如序列表中的SEQ ID NO.5所示
rs1107788
Figure PCTCN2017092505-appb-000006
如序列表中的SEQ ID NO.6所示
rs11074854
Figure PCTCN2017092505-appb-000007
如序列表中的SEQ ID NO.7所示
rs1859309
Figure PCTCN2017092505-appb-000008
如序列表中的SEQ ID NO.8所示
rs1859308
Figure PCTCN2017092505-appb-000009
如序列表中的SEQ ID NO.9所示
rs1859307
Figure PCTCN2017092505-appb-000010
如序列表中的SEQ ID NO.10所示
rs 201883233
Figure PCTCN2017092505-appb-000011
如序列表中的SEQ ID NO.11所示
rs1859306
Figure PCTCN2017092505-appb-000012
如序列表中的SEQ ID NO.12所示
rs11074855
Figure PCTCN2017092505-appb-000013
如序列表中的SEQ ID NO.13所示
rs10852316
Figure PCTCN2017092505-appb-000014
如序列表中的SEQ ID NO.14所示
rs7199163
Figure PCTCN2017092505-appb-000015
如序列表中的SEQ ID NO.15所示
rs982204
Figure PCTCN2017092505-appb-000016
如序列表中的SEQ ID NO.16所示；
rs72535012
Figure PCTCN2017092505-appb-000017
如序列表中的SEQ ID NO.17所示；
rs1116973
Figure PCTCN2017092505-appb-000018
如序列表中的SEQ ID NO.18所示
rs2382582
Figure PCTCN2017092505-appb-000019
如序列表中的SEQ ID NO.19所示
rs2189521
Figure PCTCN2017092505-appb-000020
如序列表中的SEQ ID NO.20所示
rs58579343
Figure PCTCN2017092505-appb-000021
表2与原发性胆汁性胆管炎显著关联的IL21R基因区域单核苷酸多态性位点
Figure PCTCN2017092505-appb-000022
Figure PCTCN2017092505-appb-000023
其中“OR(95％CI)”，表示与携带正常的单倍体的个体相比，携带疾病相关单倍体的个体发生PBC的相对风险。染色体位置为参照Human Genome GRCh37/hg19.。
实施例2rs10852316，rs2189521的验证实验
通过针对其中的rs10852316，rs2189521在907个PBC患者和2027个正常对照的验证，同样发现有显著差异。PBC患者验证样品与实施例1中的标准一样；分析正常对照样品来自东南大学教师体检，生化指标正常，B超检查无肝脾异常，无临床疾病表征，自述体健。验证实验实施中的材料和时间如无说明，均由Sequenom公司提供。
1、验证IL21R基因区域单核苷酸多态性位点序列
rs10852316序列
Figure PCTCN2017092505-appb-000024
rs2189521
Figure PCTCN2017092505-appb-000025
2、引物设计
使用Sequenom公司Genotyping Tools及MassARRAY Assay Design软件设计待测SNP位点的PCR扩增引物及单碱基延伸引物，并交由Integrated DNA Technologies合成。
设计使用DNA引物和探针如下：
rs10852316：
引物1序列，ACGTTGGATGGGTTATTTTTCCCAGATTCC；
引物2序列，ACGTTGGATGCTGGGTGGTGGGAATTTTTA；
探针序列，aggggTCCCAGATTCCAGAAGTAAGA
rs2189521：
引物1序列，ACGTTGGATGTGTCAGCCACACTCAGGGA；
引物2序列，ACGTTGGATGAGACCCACTGGCGTCTCTCT；
探针序列，tctttCCAGACGCCGAGCTTAC
3、PCR扩增
PCR扩增采用多重PCR技术，在384孔板中进行，每个反应体系总体积为5μl。在一个新的1.5ml EP管中配制PCR master mix溶液。
配制PCR master mix液：
PCR Mix对每个反应，μL
10×PCR Buffer 0.5μL
MgCl2(25mM)0.4μL
dNTP mix(25mM)0.1μL
HotStar Taq(5U/μL)0.1μL
Water 1.9μL
PCR primer mix(引物1和2各0.5pmol)1μL
Total Volume4μL
使用24通道加样器，调节加样体积为4μL，在384孔板的每个加样孔中加入PCR master mix液。该384孔板即为PCR反应板。取出已经制备好的DNA样品384孔板，使用24通道加样器，调节加样体积为1μL，每个5μlPCR反应体系中包含模板DNA 20-50ng，Hotstar Taq 0.5U，每条扩增引物0.5pmol，0.1μl的25mM dNTPs。在兼容384孔板的PCR仪上设定PCR反应条件为：94℃4分钟；94℃20秒，56℃30秒，72℃1分钟，45个循环；72℃3分钟；4℃保持。将384孔PCR反应板放置于PCR仪上，启动PCR反应。
4、PCR产物碱性磷酸酶处理
在PCR反应结束后，将PCR产物用SAP(shrimp alkaline phosphatase，虾碱性磷酸酶)处理，以去除体系中游离的dNTPs。
(1)配制碱性磷酸酶处理反应液，SAP Mix。
SAP Mix对每个反应，μL
H2O1.53
SAP Buffer(10x)0.17
SAP Enzyme(1.7U/μL)0.3
Total Volume 2
(2)使用24通道加样器，调节加样体积为2μL，将SAP Mix加入384孔PCR反应板。对于每个碱性磷酸酶处理反应孔，反应体系总体积为7μl，其中PCR产物5μl，SAP Mix 2μl。
(3)将384孔板放置在兼容384孔板的PCR仪上，设定PCR反应条件：37℃40分钟；85℃5分钟；4℃维持，启动PCR仪进行碱性磷酸酶处理。
5、单碱基延伸
(1)在碱性磷酸酶处理结束后，进行单碱基延伸反应，反应体系总体积9μl。
(2)配制单碱基延伸反应液，EXTEND Mix。
Figure PCTCN2017092505-appb-000026
(3)使用24通道加样器，调节加样体积为2μL，将EXTEND Mix对应加入384孔反应板。对于每个反应孔，单碱基延伸反应体系包含SAP处理后PCR产物7μl及EXTEND Mix液2μl(其中各延伸反应引物混合物0.94μl，iPLEX酶0.041μl,延伸混合物0.2μl)。
(4)将384孔板放置在兼容384孔板的PCR仪上，设定PCR反应条件：
I.94℃ for 30seconds；
II.94℃ for 5seconds；
III.52℃ for 5seconds；
IV.80℃ for 5seconds；
V.GOTO III，4more times；
VI.GOTO II，39more times；
VII.72℃ for 3minutes；
VIII.4℃ forever；
启动PCR仪进行单碱基延伸反应。
6、树脂纯化
(1)将Clean Resin树脂平铺到6mg的树脂板中；
(2)加16μl水到延伸产物的对应孔内；
(3)将干燥后的树脂倒入延伸产物板中，封膜，低速垂直旋转30分钟，使树脂与反应物充分接触；
(4)离心使树脂沉入孔底部。
7、芯片点样
启动MassARRAY Nanodispenser RS1000点样仪，将树脂纯化后的延伸产物移至384孔SpectroCHIP芯片上。
8、质谱检测
将点样后的SpectroCHIP芯片使用MALDI-TOF(matrix-assisted laser desorption/ionization–time of fligh，基质辅助激光解吸附电离飞行时间质谱)分析，检测结果使用TYPER 4.0软件(sequenom)分型并输出结果。共907个PBC样品和2127个对照样品得到了有效的结果。
采用PLINK软件，逻辑回归原理进行，以性别为共变量，按叠加效应模型对907个PBC样品和2127个对照样品的结果进行了统计分析。rs10852316的疾病相关单倍体(G)频率在PBC中(0.626)显著高于对照人群(0.556)，p值为5.59×10-7。rs2189521的疾病相关单倍体(A)频率在PBC中(0.754)显著高于对照人群(0.680)，p值为9.87×10-9。将1,122PBC病人和4,036正常对照的GWAS结果，与在907个PBC样品和2127个对照样品的结果进行叠加分析，采用fixed-effect model(I2<25％)的原理，统计分析共包括2029个PBC样品和6163个对照样品。结果表明：rs10852316的疾病相关单倍体(G)频率在PBC中显著高于对照人群，p值为2.76×10-13，相对危险度值(96％CI)为1.32(1.22-1.41)；rs2189521的疾病相关单倍体(A)频率在PBC中显著高于对照人群，p值为4.00×10-16，相对危险度值(96％CI)为1.41(1.28-1.52)(见表3)。
表3：IL21R多态位点rs10852316，rs2189521在全基因组关联分析和验证发现中的结果
Figure PCTCN2017092505-appb-000027
实施例3原发性胆汁性胆管炎患者肝脏组织中IL21R的表达分析
所有肝组织，包括30例PBC患者，30例自身免疫肝炎(AIH)患者，25例慢性乙型肝炎(CHB)患者均为在上海仁济医院超声指导的肝活检组织。6例健康对照(HC)的肝脏组织来自肝脏移植供体。肝组织经福尔马林固定和石蜡包埋保存。肝组织的炎症和纤维化程度按照“Scheuer”评分系统评定。
1、肝组织切片在柠檬酸钠缓冲液中浸泡20分钟；
2、加入1:150稀释的抗IL21R抗体(ab13268，Abcam，Cambridge,USA)，室温保持20分钟；
3、用磷酸钠缓冲液清洗玻片；
4、加入1:2000稀释的辣根过氧化酶标记的羊抗兔抗体(全自动免疫组化机二抗组合，47101，Leica)，采用Leica全自动免疫组化机进行免疫组化染色操作；
5、对染色的玻片进行分析，在40*10放大的显微镜下随即选取5个镜下区域，记录染色的阳性细胞数，最终结果按平均值加标准差表述。Mann–Whitney U分析原理(Mann–Whitney U-test)用于数据的统计分析，P值小于0.05被认为统计学显著差异。所有分析采用Prism软件系统(Prism software Version 6.0，Graphpad Software,La Jolla,CA,USA).进行处理。
结果表明，相比于乙型肝炎，自身免疫性肝炎和正常肝组织，IL21R在PBC患者肝组织中表达显著升高。在PBC患者中，IL21R表达的细胞通常是聚集在炎症的肝脏门管区中，尤其是在损伤的小叶间胆管周边。实验结果表明，IL21R阳性细胞的数目与肝脏的炎症程度和肝脏的纤维化程度呈正比。统计分析发现IL21R阳性细胞的数目与肝脏的炎症程度正相关(r＝0.43，p<0.05)；与肝脏的的纤维化程度正相关(r＝0.60，p<0.01)，相关结果见图2。
上述仅为本发明优选的实施例，对于本领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出其它不同形式的变化或变动，这些也应属于本发明的保护范围。
Figure PCTCN2017092505-appb-000028
Figure PCTCN2017092505-appb-000029
Figure PCTCN2017092505-appb-000030
Figure PCTCN2017092505-appb-000031
Figure PCTCN2017092505-appb-000032
Figure PCTCN2017092505-appb-000033

Claims (8)

  1. IL21R在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用。
  2. IL21R基因多态位点rs1859308的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用，rs1859308序列如序列表中的SEQ ID NO.8所示，其中，单核苷酸n为C的携带者原发性胆汁性胆管炎的风险高于等位基因T。
  3. IL21R基因多态位点rs201883233的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用，rs201883233序列如序列表中的SEQ ID NO.10所示，其中，单核苷酸n为A的携带者原发性胆汁性胆管炎的风险高于等位基因C。
  4. IL21R基因多态位点rs10852316的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用，rs10852316序列如序列表中的SEQ ID NO.13所示，其中，单核苷酸n为C的携带者原发性胆汁性胆管炎的风险高于等位基因A。
  5. IL21R基因多态位点rs2189521的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用，rs2189521序列如序列表中的SEQ ID NO.19所示，其中，单核苷酸n为A的携带者原发性胆汁性胆管炎的风险高于等位基因G。
  6. IL21R基因多态位点rs58579343的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用，rs58579343序列如序列表中的SEQ ID NO.20所示，其中，单核苷酸n为A的携带者原发性胆汁性胆管炎的风险高于等位基因G。
  7. IL21R在制备PBC动物模型中的应用。
  8. IL21R在制备PBC治疗药物方面的应用。
PCT/CN2017/092505 2017-01-10 2017-07-11 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用 Ceased WO2018129888A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710015653.0 2017-01-10
CN201710015653.0A CN106834449B (zh) 2017-01-10 2017-01-10 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用

Publications (1)

Publication Number Publication Date
WO2018129888A1 true WO2018129888A1 (zh) 2018-07-19

Family

ID=59118411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/092505 Ceased WO2018129888A1 (zh) 2017-01-10 2017-07-11 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用

Country Status (2)

Country Link
CN (1) CN106834449B (zh)
WO (1) WO2018129888A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117357508A (zh) * 2023-11-03 2024-01-09 中山大学孙逸仙纪念医院 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1404400A (zh) * 2000-02-21 2003-03-19 应用研究系统Ars股份公司 Il－18抑制剂的应用
WO2010102387A1 (en) * 2009-03-09 2010-09-16 University Health Network (Uhn) Interleukin-12 polymorphisms for identifying risk for primary biliary cirrhosis
CN103602671A (zh) * 2013-10-16 2014-02-26 中国人民解放军第四军医大学 一种krt8基因外显子区域中snp位点及其确定方法
CN103749388A (zh) * 2014-01-16 2014-04-30 中国科学技术大学 培育作为肝纤维化与原发性胆汁性肝硬化动物模型的IL-12p40(-/-)IL-2Rα(-/-)小鼠的方法
CN106834449A (zh) * 2017-01-10 2017-06-13 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1404400A (zh) * 2000-02-21 2003-03-19 应用研究系统Ars股份公司 Il－18抑制剂的应用
WO2010102387A1 (en) * 2009-03-09 2010-09-16 University Health Network (Uhn) Interleukin-12 polymorphisms for identifying risk for primary biliary cirrhosis
CN103602671A (zh) * 2013-10-16 2014-02-26 中国人民解放军第四军医大学 一种krt8基因外显子区域中snp位点及其确定方法
CN103749388A (zh) * 2014-01-16 2014-04-30 中国科学技术大学 培育作为肝纤维化与原发性胆汁性肝硬化动物模型的IL-12p40(-/-)IL-2Rα(-/-)小鼠的方法
CN106834449A (zh) * 2017-01-10 2017-06-13 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HIRSCHFIELD, G.M.: "Primary Biliary Cirrhosis Associated with HLA, IL 12A, and IL 12RB2 Variants", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 24, 20 May 2009 (2009-05-20), XP055508689 *
LI, Y.Y. ET AL: "Chemokine (C-X-C Motif) Ligand 13 Promotes Intrahepatic Chemokine (C-X-C Motif) Receptor 51 Lymphocyte Homing and Aberrant B-Cell Immune Responses in Primary Biliary Cirrhosis", HEPATOLOGY, vol. 61, no. 6, 30 June 2015 (2015-06-30), pages 1998 - 2007, XP055508699 *
MELLS, G.F.: "Genome-wide association study identifies 12 new susceptibi- lity loci for primary biliary cirrhosis", NATURE GENETICS, vol. 43, no. 4, 30 April 2011 (2011-04-30), XP055508575 *
QIU, F.: "A genome-wide association study identifies six novel risk loci for primary biliary cholangitis", NATURE COMMUNICATIONS, 20 April 2017 (2017-04-20), XP055508568 *
YANG, Y.Q: "Dysregulation of peritoneal cavity Bla cells and murine pri- mary biliary cholangitis", ONCOTARGET, vol. 7, no. 19, 20 April 2016 (2016-04-20), XP055508681 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117357508A (zh) * 2023-11-03 2024-01-09 中山大学孙逸仙纪念医院 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用
CN117357508B (zh) * 2023-11-03 2024-05-17 中山大学孙逸仙纪念医院 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用

Also Published As

Publication number Publication date
CN106834449A (zh) 2017-06-13
CN106834449B (zh) 2019-04-30

Similar Documents

Publication Publication Date Title
CN103757104B (zh) 用于鼻咽癌发病风险预测的试剂盒及基因芯片
JP2019062899A (ja) 肝臓病変を評価する方法
CN102399898B (zh) 一种与临床原因不明的非梗阻性无精子症辅助诊断相关的snp标志物及其应用
CN112980949B (zh) 一种用于鼻咽癌高危人群识别的snp标志物及其试剂盒和应用
CN104109716B (zh) 一种人类hla-b27基因分型试剂盒
CN103492570A (zh) 一种强直性脊柱炎相关特异性单核苷酸多态性的检测方法及其试剂盒
CN104988141B (zh) BRCA2基因g.32912799T＞C突变及其在乳腺癌辅助诊断中的应用
WO2018129888A1 (zh) 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
WO2018129887A1 (zh) 与原发性胆汁性胆管炎关联的白细胞介素21及其应用
WO2018129886A1 (zh) 与原发性胆汁性胆管炎关联的白细胞介素16及其应用
CN105112415A (zh) 用于2型糖尿病患病风险评估的遗传位点rs780092及检测试剂盒
JP6494356B2 (ja) 非アルコール性脂肪性肝疾患及び／又は非アルコール性脂肪肝炎の発症リスク及び／又は重症化リスクの判定方法、並びに該判定用オリゴヌクレオチドキット
CN107557468A (zh) 一种与原发性肺癌辅助诊断相关的癌‑睾丸基因遗传标志物及其应用
CN101294201A (zh) 冠心病检测方法和试剂盒
CN104164427B (zh) 一种与吸烟成瘾相关的snp标志物及其应用
TWI783352B (zh) 評估罹患子宮頸癌之風險之方法
CN101871003A (zh) 预测中国人2型糖尿病易感性的试剂盒及引物
CN104263822B (zh) 一种与临床原因不明的noa辅助诊断相关的低频snv标志物及其应用
CN116411068A (zh) 与单纯法洛四联症相关的tbx1基因非编码突变及其应用
CN104263724B (zh) 一种与散发型非综合征型chd辅助诊断相关的低频snv标志物及其应用
WO2023236189A1 (zh) 利用非完整重组的t细胞受体核苷酸序列诊断t细胞淋巴瘤的方法及试剂盒
CN103215265B (zh) 一种老年黄斑变性疾病的筛查试剂盒
TW202348803A (zh) 利用非完整重組的ｔ細胞受體核苷酸序列診斷ｔ細胞淋巴瘤的方法及套組
CN105039543A (zh) 可用于检测与2型糖尿病相关的ptpn1基因启动子区甲基化程度的试剂盒及其应用
CN120591391A (zh) ITGA2突变位点rs35235在诊断冠脉CTO中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17891093

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17891093

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17891093

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 14/05/2020)

122 Ep: pct application non-entry in european phase

Ref document number: 17891093

Country of ref document: EP

Kind code of ref document: A1